Analysts at StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the medical instruments supplier’s stock.
Atrion Price Performance
ATRI stock opened at $459.66 on Friday. Atrion has a 1 year low of $274.98 and a 1 year high of $503.24. The company has a 50 day simple moving average of $455.77 and a 200 day simple moving average of $428.16. The stock has a market cap of $809.00 million, a price-to-earnings ratio of 43.20 and a beta of 0.69.
Atrion (NASDAQ:ATRI – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $48.77 million during the quarter.
Institutional Investors Weigh In On Atrion
Atrion Company Profile
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More
- Five stocks we like better than Atrion
- What Investors Need to Know About Upcoming IPOs
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What Is WallStreetBets and What Stocks Are They Targeting?
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 REITs to Buy and Hold for the Long Term
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.